Medical Devices Startups
6,372 companies tagged Medical Devices, with their investors and founders.
Xerient is a biopharmaceutical company developing oncology treatments, with expertise in clinical trial design, radiation oncology, and translational cancer research for gastrointestinal malignancies.
2 investors
XGenomes develops genomic sequencing technology using fluorescent probes and machine learning to read genetic and epigenetic information at single-molecule resolution. The platform enables frequent, rapid, and low-cost screening for healthcare providers and patients to support early disease detection and personalized preventive medicine.
2 investors
xMD Diagnostics develops laboratory instruments and consumables for molecular diagnostics, aimed at enriching samples for downstream molecular testing. It serves research, biopharmaceutical, and clinical (CLIA) laboratories to help pathologists, oncologists, and other physicians diagnose, monitor, and treat cancer and other genetic diseases.
2 investors
XN Health develops a medical device that uses phrenic nerve stimulation to prevent ventilator-induced lung injury in mechanically ventilated patients by inducing diaphragm contractions. The device is intended for healthcare providers managing patients requiring mechanical ventilation support.
2 investors
Xolo develops volumetric 3D printing technology using photo-switchable molecules controlled by light, enabling single-pass production of entire objects rather than layer-by-layer printing. The company targets multiple industries including dental, optics, bioengineering, and semiconductors.
2 investors
XRHealth develops and distributes a VR-based cognitive behavioral therapy device prescribed as durable medical equipment for pain management, stress relief, and mental health support. The device is Medicare-covered and FDA-registered, targeting healthcare providers and patients seeking immersive at-home therapy solutions.
2 investors
YPrime provides a clinical trial technology platform with patient engagement features (eConsent and eCOA) designed to accelerate trial timelines, improve data quality, and enhance participant experience for pharmaceutical companies, biotechs, and contract research organizations.
2 investors
Yellowbird Diagnostics develops plug-and-play imaging dyes for common medical imaging procedures, designed to reveal disease markers for earlier diagnosis of conditions affecting the brain, heart, and kidneys. The products are aimed at clinicians and patients needing early diagnosis of these diseases.
2 investors
Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
2 investors
Zeto develops improved electroencephalography technology for diagnosing epilepsy and other neurological conditions. The company serves physicians and medical institutions seeking advanced EEG diagnostic tools.
2 investors
ZYMEDI is a drug discovery company that partners through R&D joint ventures, strategic investments, and in-licensing arrangements. It works with collaborators across the pharmaceutical and biotechnology sector.
2 investors
Surginex develops lipid nanoparticle and RNA platforms for therapeutic applications, serving pharmaceutical and biotech companies in drug development.
2 investors
Exosystems develops AI-based digital biomarkers for the assessment, monitoring, and treatment of neuromuscular and musculoskeletal disorders, supporting diagnosis, severity assessment, and disease progression tracking for conditions such as stroke, Parkinson's, ALS, SMA, sarcopenia, and myasthenia gravis. Its technology aims to provide faster, non-invasive, and reproducible quantitative neuromuscular evaluations for clinical and healthcare settings.
2 investors
L&K Biomed develops spinal medical devices and related surgical products. The company focuses on research and development of orthopedic and spine healthcare technology.
2 investors
Airato is a Japanese medical device startup developing AI-powered software for radiation therapy planning and delivery. The company aims to improve cancer treatment outcomes and quality of life for patients through advanced radiation oncology technology.
2 investors
AccuRna develops drug delivery systems for nucleic acid therapeutics, including antisense oligonucleotides, siRNA, miRNA, and mRNA-based treatments. The company focuses on enabling the development of novel medicines for refractory diseases with no current cure.
2 investors
IMMUNOSENS manufactures in vitro diagnostic pharmaceuticals and third-class medical devices for clinical diagnostic purposes. The company holds regulatory approvals from Japanese authorities for these medical products.
2 investors
AI Silk manufactures and sells lead skins (electrodes) and related electrode application products. The company serves medical and industrial sectors requiring specialized electrode technology.
2 investors
Cuorips develops regenerative medicine products based on human iPS cell technology, including its heart muscle cell sheet "Heart®" (Rehart) for treating severe heart failure caused by ischemic cardiomyopathy, along with catheter-based therapies and compound drugs (YS series). The Japan-based company, spun out of Osaka University research, also builds cell mass-manufacturing infrastructure (VMaCS) and is listed on the Tokyo Stock Exchange Growth market.
2 investors
Kringle Pharma develops and manufactures HGF protein-based pharmaceuticals for treating conditions including spinal cord injury, ALS, and vocal cord scarring. The company is a spin-out of Osaka University and Keio University focused on drug development in the biotech sector.
2 investors
Toregem Biopharma is a Kyoto University spin-off developing a tooth-regeneration drug based on a humanized anti-USAG-1 antibody that aims to regrow teeth with a single injection. It initially targets patients with congenital tooth agenesis (a rare genetic condition) and ultimately aims to treat tooth loss from decay or periodontal disease.
2 investors
Hynts Technology develops nanotechnology-based products for cellular delivery and extraction applications. The company offers nanostructured membrane stamps, microscope-mounted stamping systems, and cell processing services for research and biotech applications.
2 investors
FIMECS, Inc. is a Japanese drug discovery company researching and developing new pharmaceuticals based on targeted protein degradation mechanisms.
2 investors
BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.
2 investors